However, alternative mechanisms include direct effects of phosphate on endothelial function, and effects mediated by regulators of phosphate homoeostasis, including fibroblast growth factor 23 (FGF-23), a phosphaturic hormone implicated in cardiac hypertrophy, another common feature of CKD [4, 28–31]. Here, FGF23 is linked to cardiac hypertrophy.